Using mebendazole to help treat colon cancer
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
This study is testing if adding mebendazole to standard chemotherapy can help people with stage 4 colon cancer respond better to treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT03925662 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of mebendazole as an adjuvant treatment for patients with stage 4 colorectal cancer. Participants will receive a combination of standard chemotherapy (Folfox with Avastin) alongside mebendazole to evaluate its effectiveness in improving treatment outcomes. The study aims to determine whether adding mebendazole can enhance the overall response to treatment in this advanced cancer stage. The approach is based on the potential of mebendazole to exert anti-cancer effects in addition to its antiparasitic properties.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with stage 4 colorectal cancer.
Not a fit: Patients with agranulocytosis, those who are pregnant, or individuals allergic to mebendazole may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve survival rates and quality of life for patients with advanced colorectal cancer.
How similar studies have performed: While the use of mebendazole in cancer treatment is an emerging area, there is limited prior evidence, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Colorectal cancer stage 4. Exclusion Criteria: * Agranulocytosis * Pregnancy * Allergy to mebendazole.
Where this trial is running
Cairo
- Sherief Abd-Elsalam — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Reham El-ghoneimy, Msc — Tanta University - Faculty of Pharmacy
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.